Search Results - "Massari, F E"

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor by Condra, J H, Holder, D J, Schleif, W A, Blahy, O M, Danovich, R M, Gabryelski, L J, Graham, D J, Laird, D, Quintero, J C, Rhodes, A, Robbins, H L, Roth, E, Shivaprakash, M, Yang, T, Chodakewitz, J A, Deutsch, P J, Leavitt, R Y, Massari, F E, Mellors, J W, Squires, K E, Steigbigel, R T, Teppler, H, Emini, E A

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Combination Therapy with Zidovudine Prevents Selection of Human Immunodeficiency Virus Type 1 Variants Expressing High-Level Resistance to L-697,661, a Nonnucleoside Reverse Transcriptase Inhibitor by Staszewski, S., Massari, F. E., Kober, A., Göhler, R., Durr, S., Anderson, K. W., Schneider, C. L., Waterbury, J. A., Bakshi, K. K., Taylor, V. I., Hildebrand, C. S., Kreisl, C., Hoffstedt, B., Schleif, W. A., von Briesen, H., Rübsamen-Waigmann, H., Calandra, G. B., Ryan, J. L., Stille, W., Emini, E. A., Byrnes, V. W.

“…L-697,661 is a human immunodeficiency virus type 1 (HIV-l)-specific nonnucleoside reverse transcriptase (RT) inhibitor. Its tolerability and activity in…”
Get full text

Denosumab: an update by Bogado, Cesar E, Boailchuk, J A, Zanchetta, M B, Massari, F E, Zanchetta, J R

“…Denosumab is a fully human monoclonal antibody that inhibits the formation, function and survival of osteoclasts, preventing the interaction of tumor necrosis…”
Get full text

In vivo T lymphocyte origin of macrophage-tropic strains of HIV. Role of monocytes during in vitro isolation and in vivo infection by Massari, FE, Poli, G, Schnittman, SM, Psallidopoulos, MC, Davey, V, Fauci, AS

“…Previously published isolation techniques with T cell blasts and monocyte-derived macrophages (MDM) were used to recover HIV from the PBMC of a group of 23…”
Get full text

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial by Langdahl, Bente L, Libanati, Cesar, Crittenden, Daria B, Bolognese, Michael A, Brown, Jacques P, Daizadeh, Nadia S, Dokoupilova, Eva, Engelke, Klaus, Finkelstein, Joel S, Genant, Harry K, Goemaere, Stefan, Hyldstrup, Lars, Jodar-Gimeno, Esteban, Keaveny, Tony M, Kendler, David, Lakatos, Peter, Maddox, Judy, Malouf, Jorge, Massari, Fabio E, Molina, Jose Fernando, Ulla, Maria Rosa, Grauer, Andreas

“…Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a…”
Get full text

Efficient macrophage isolation of human immunodeficiency virus from peripheral blood leukocytes from healthy seropositive individuals: implications for cell tropism by Poli, G, Massari, F E, Schnittman, S M, Psallidopoulos, M C, Davey, V, Lane, H C, Fauci, A S

“…We investigated the efficiency of HIV isolation from the PBL of 23 healthy, HIV-seropositive individuals with high (600-700/mm3) CD4+ T cell counts…”
Get more information

A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase by Saag, Michael S, Emini, Emilio A, Laskin, Oscar L, Douglas, Jeffrey, Lapidus, William I, Schleif, William A, Whitley, Richard J, Hildebrand, Carol, Byrnes, Vera W, Kappes, John C, Anderson, Kevin W, Massari, Ferdinand E, Shaw, George M

“…Current treatment of human immunodeficiency virus type 1 (HIV-1) infection consists exclusively of the nucleoside-analogue reverse transcriptase inhibitors…”
Get full text

Denosumab: What’s New? by Bogado, Cesar E., Zanchetta, Maria Belen, Boailchuk, Juan A., Massari, Fabio E., Zanchetta, Jose R.

“…Denosumab is the first fully human monoclonal antibody that inhibits the formation, function, and survival of osteoclasts by blocking the interaction of…”
Get full text

Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase by STASZEWSKI, S, MASSARI, F. E, HILDEBRAND, C. S, KREISL, C, HOFFSTEDT, B, SCHLEIF, W. A, VON BRIESEN, H, RÜBSAMEN-WAIGMANN, H, CALANDRA, G. B, RYAN, J. L, STILLE, W, EMINI, E. A, KOBER, A, BYRNES, V. W, GÖHLER, R, DURR, S, ANDERSON, K. W, SCHNEIDER, C. L, WATERBURY, J. A, BAKSHI, K. K, TAYLOR, V. I

Get full text